医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Milestone in Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb

2015年06月11日 PM03:38
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today the achievement of a milestone in one of the discovery programs in its alliance with US-based Bristol-Myers Squibb (NYSE:BMY). The milestone is the decision by Bristol-Myers Squibb to designate a Collaboration Compound as a candidate for exploratory clinical development, indicating that the compound has met certain pre-defined criteria and is now suitable for exploratory clinical development. The compound will now proceed to IND-enabling studies. Achievement of this milestone entitles PeptiDream to receive an undisclosed payment specified in the research collaboration and license agreement between PeptiDream and Bristol-Myers Squibb initiated October 15, 2010 and extended on October 15, 2012.

[Comments from Kiichi Kubota, President & CEO of PeptiDream Inc]

“We are very excited about the acceptance of a Collaboration Compound as a candidate for clinical development by Bristol-Myers Squibb. This is the first compound identified in the discovery collaboration to enter IND-enabling studies for Bristol-Myers Squibb and we look forward to its transition to clinical investigation. This decision by Bristol-Myers Squibb represents a key validation of PeptiDream’s peptide discovery platform and its ability to identify compounds that can be optimized for clinical studies. ”

About PeptiDream Inc.

In the past five years, PeptiDream has established funded discovery collaborations with many leading pharmaceutical companies, such as Amgen, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Merck, Mitsubishi Tanabe, Daiichi Sankyo, as well as a strategic collaboration with Ipsen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb and Novartis.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150610006494/en/

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持